$DCBO

Docebo Inc. Announces Substantial Issuer Bid, Preliminary Unaudited Second Quarter 2026 Financial Results, Initial Q3-2026 and Revised FY2026 Guidance

Docebo Inc. (NASDAQ: DCBO, TSX: DCBO) said its board approved a substantial issuer bid to repurchase up to US$70m of common shares at US$20.40 each, funded by about US$10m cash and a US$60m credit-facility draw. Preliminary Q2 2026 results: subscription revenue US$63.5-63.7m, total revenue US$68.3-68.5m, adjusted EBITDA US$10.9-11.1m. Full results due Aug 7, 2026.

Original reporting
Published Jul 17, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Docebo Inc. Announces Substantial Issuer Bid, Preliminary Unaudited Second Quarter 2026 Financial Results, Initial Q3-2026 and Revised FY2026 Guidance — source image
Decision brief

The 30-second read

$DCBOBullishMed
01

Why it matters

Traders can frame this as a two-part catalyst: (1) a defined buyback price and size that can affect near-term supply/demand and sentiment, and (2) preliminary operating metrics that set expectations for the Aug 7 full report and any revised Q3/FY guidance.

02

Market read

The fixed-price issuer bid and preliminary growth ranges are concrete inputs for positioning into the Aug 7 full Q2 print, with potential volatility around confirmation of guidance and cash/leverage implications.

03

What to watch

The preliminary figures are unaudited and subject to audit committee review; also, the concentration shift in the largest OEM customer (2.5% of ARR vs 8.4%) could be a key driver of quality of growth.

Relevance 8/10Novelty 7/10Timing: ahead of the Aug 7 pre-market full Q2-2026 results and the July 21 mailing of offer documents

Background

Docebo announced a substantial issuer bid (up to $70M at $20.40) and preliminary unaudited Q2-2026 results, with full results scheduled for Aug 7.

Company-level read

Ticker impact

$DCBOBullishMedium confidence
Context

Docebo approved a substantial issuer bid to repurchase up to $70M of shares at $20.40, alongside preliminary Q2 revenue and EBITDA ranges.

Expected impact

Likely near-term support from buyback optics, with volatility into the Aug 7 full Q2 print as investors validate the preliminary ranges and guidance.

Evidence & confidence

The article discloses concrete buyback terms and preliminary financial ranges, which are actionable for positioning, but it does not provide the revised FY2026/Q3 guidance numbers in the scraped text, limiting conviction on fundamentals.

Market effects

Signals continued capital return willingness from an enterprise learning/AI workforce software name, potentially supportive for sentiment in adjacent HR/LMS software peers.

May influence Canadian-listed small-cap sentiment via the TSX listing and CAD payment option, but impact is likely localized.

Limited broader market relevance; primarily company-specific capital allocation and near-term earnings setup.

Counterpoint

The buyback is funded partly by a credit facility draw, so investors may discount the support if leverage or cash flow durability is questioned.

Key entities

  • Docebo Inc.

    NASDAQ: DCBO, TSX: DCBO. Approved issuer bid and provided preliminary Q2-2026 revenue, subscription revenue, and adjusted EBITDA ranges.

  • Intercap Inc.

    Beneficially owns ~63.9% of Docebo and intends to participate to maintain its ownership percentage.

  • Canaccord Genuity Corp.

    Engaged as financial advisor for the issuer bid.

  • TSX Trust Company

    Acts as depositary for the issuer bid.

Related articles

$DCBOHigh

Docebo’s (DCBO) Revenue Soars While Profits Quietly Slip

Docebo (DCBO) reported Q2 2026 revenue up 13% YoY to $68.7M, with subscription revenue at $63.8M. CEO Artuffo cited AI-driven workforce transformations. Adjusted EBITDA rose 21.8% to $11.2M, but GAAP net income fell 26.6% to $2.3M. Free cash flow dropped 73% to $3.1M. The company raised its full-year outlook and reduced customer concentration risk.

$DCBOMed

Docebo Inc. (DCBO): Financial results for Q2 2026

Docebo Inc. (DCBO) furnished an SEC Form 6-K — earnings release. Docebo Reports Second Quarter 2026 Results TORONTO, ONTARIO - August 7, 2026 - Docebo Inc. (NASDAQ: DCBO; TSX:DCBO) (“ Docebo ” or the “ Company ”), the Enterprise Platform for the AI-era workforce, unifying skills intelligence, learning, and knowledge in one closed loop, announc

$PHOSMed

First Phosphate shareholders could see reduced dilution risk, Noble says after SERV news

First Phosphate Corp. (PHOS) may face reduced equity dilution after Noble Capital Markets noted potential lower funding needs for its Bégin-Lamarche project, supported by Swiss Export Risk Insurance (SERV) and other financing. SERV could provide up to US$212.5 million, reducing the equity requirement to about US$82.5 million. Noble maintains an Outperform rating and $25.50 price target.